CSL Behring: Clinical Trials

154 completed, 22 terminated, 21 recruiting, 8 unknown. 66 Phase 3, 60 Phase 2, 34 Phase 1, 21 Phase 4, 12 Not applicable.

By phase and status

Phase	Trials	Status
Phase 3	66	Completed 50, Terminated 9, Recruiting 6, Withdrawn 1
Phase 2	60	Completed 40, Terminated 7, Recruiting 5, Withdrawn 5, Unknown 2, Active not recruiting 1
Phase 1	34	Completed 24, Terminated 6, Withdrawn 3, Recruiting 1
Phase 4	21	Completed 16, Recruiting 3, Terminated 1, Unknown 1
Not applicable	12	Completed 9, Unknown 2, Withdrawn 1

Follow CSL Behring: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Phase 4, Double-blind Study Evaluating the Response on Computed Tomography (CT) Lung Density Decline Rates of Respreeza / Zemaira Weekly for 3 Years in Adults With alpha1 Antitrypsin Deficiency (AATD) CE1226 - Alpha1 Antitrypsin Deficiency, Alpha1-Proteinase Inhibitor Deficiency	Phase 4	Recruiting	CSL Behring	270	2026-09-29	2026-10-16
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies IgPro20 - Secondary Immune Deficiency	Phase 3	Recruiting	CSL Behring	63	2026-09-15	2026-10-14
A Phase 1b Study to Evaluate the PK of CSL300 (Clazakizumab) in Chinese Subjects With End Stage Kidney Disease (ESKD) CSL300, Placebo - End Stage Kidney Disease (ESKD)	Phase 1	Recruiting	CSL Behring	24	2026-06-17	2026-07-07
Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD) Anumigilimab, Placebo - Sickle Cell Disease	Phase 2	Recruiting	CSL Behring	63	2026-02-02	2026-08-05
Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary Hemochromatosis Vamifeport, Placebo - Homeostatic Iron Regulator Gene-related Hereditary Hemochromatosis	Phase 2	Active not recruiting	CSL Behring	84	2026-01-22	2026-10-21
Efficacy and Safety of 4F-PCC (4-Factor Prothrombin Complex Concentrate) in Adult Patients Undergoing Complex Cardiovascular Surgery With Cardiopulmonary Bypass (CPB) BE1116, FFP - Complex Cardiovascular Surgery With Cardiopulmonary Bypass	Phase 3	Recruiting	CSL Behring	200	2025-09-15	2026-10-15
Dose Range Finding, Efficacy, and Safety Study of Nebulized CSL787 in Adults With Non-cystic Fibrosis Bronchiectasis (NCFB) CSL787, Placebo, Nebulizer - Non-cystic Fibrosis Bronchiectasis	Phase 2	Recruiting	CSL Behring	180	2025-09-03	2026-10-19
Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B CSL222 (Adeno-associated viral vector serotype 5 [AAV5]-hFIXco-Padua) - Hemophilia B	Phase 3	Recruiting	CSL Behring	20	2025-07-28	2026-10-20
A Study Investigating the Effectiveness and Safety of Garadacimab for Treating Patients With Hereditary Angioedema (HAE) No intervention - Hereditary Angioedemas		Recruiting	CSL Behring	200	2025-07-21	2026-06-03
An Open-label, Multicenter Study to Assess the Pharmacokinetics (PK), Safety, and Tolerability of Subcutaneous IgPro20 in Immunoglobulin (IG) Treatment-naïve Participants With Primary Immunodeficiency (PID) IgPro - Primary Immunodeficiency	Phase 4	Completed	CSL Behring	8	2025-07-15	2026-07-16
Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis CSL889, Placebo - Sickle Cell Disease Vaso-occlusive Crisis	Phase 2	Recruiting	CSL Behring	70	2025-07-10	2026-10-08
Effect of Food on the Oral Bioavailability of a Prolonged-release Formulation of Vamifeport in Healthy Adults Vamifeport (PR formulation) - Healthy Volunteers	Phase 1	Completed	CSL Behring	28	2025-05-27	2025-11-21
Zemaira Eosinophilic Esophagitis Pilot Study Alpha-proteinase inhibitor - Eosinophilic Esophagitis	Phase 2	Recruiting	Children's Hospital Medical Center, Cincinnati	15	2025-05-15	2025-12-17
Safety Study in Subjects ≥ 12 Years of Age With Hereditary Angioedema Switching to Garadacimab Garadacimab - Hereditary Angioedema	Phase 4	Completed	CSL Behring	18	2025-04-28	2026-07-23
Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Participants With Hemophilia A Previously Treated With FVIII Products Recombinant single-chain factor VIII (rVIII-SingleChain) - Congenital Hemophilia A	Phase 3	Completed	CSL Behring	62	2025-01-09	2026-10-23
Pharmacokinetics and Pharmacodynamics of Two Prolonged-release Formulations of Vamifeport in Healthy Adults Vamifeport IRF, Vamifeport PR1, Vamifeport PR2 - Healthy Volunteers	Phase 1	Completed	CSL Behring	22	2024-11-22	2025-06-27
Phase 3 Study of Fibrinogen Concentrate (CSL511) in Subjects With Pseudomyxoma Peritonei Undergoing Cytoreductive Surgery CSL511 Fibrinogen concentrate (human), Cryoprecipitate - Acquired Fibrinogen Deficiency	Phase 3	Recruiting	CSL Behring	90	2024-10-01	2026-10-13
Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS IgPro20, Placebo - Post-COVID Postural Orthostatic Tachycardia Syndrome	Phase 3	Terminated	CSL Behring	16	2024-08-28	2026-04-13
Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Chinese Subjects With Hemophilia B Previously Treated With FIX Therapy Recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) - Hemophilia B	Phase 3	Completed	CSL Behring	23	2024-07-28	2026-07-23
Precision Medicine in Cardiovascular Surgery Associated Acute Kidney Injury Acute Kidney Injury, Surgery-Complications		Recruiting	Insel Gruppe AG, University Hospital Bern	100	2024-06-16	2024-07-19

Showing 20 of 217. Sign in to see all of them.

Conditions studied

Hemophilia B (24)  ·  Hemophilia A (21)  ·  Angioedemas, Hereditary (12)  ·  Primary Immunodeficiency Diseases (12)  ·  von Willebrand Diseases (11)  ·  Hemorrhage (9)  ·  Hemostatic Disorders (8)  ·  Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (8)  ·  Agammaglobulinemia (7)  ·  Common Variable Immunodeficiency (7)  ·  alpha 1-Antitrypsin Deficiency (7)  ·  Anemia, Sickle Cell (5)  ·  Blood Coagulation Disorders (5)  ·  Hereditary Angioedema Types I and II (5)  ·  Thrombosis (5)

Interventions

Hizentra (21)  ·  Immunoglobulins, Intravenous (17)  ·  Fibrinogen (13)  ·  clazakizumab (13)  ·  gamma-Globulins (13)  ·  Complement C1 Inhibitor Protein (10)  ·  Factor IX (10)  ·  Factor VIII (9)  ·  Sodium Chloride (9)  ·  alpha 1-Antitrypsin (9)  ·  Saline Solution (8)  ·  albutrepenonacog alfa (6)  ·  Fluid Therapy (4)  ·  Immunoglobulin G (4)  ·  von Willebrand Factor (4)

Countries

United States (112)  ·  Germany (68)  ·  Canada (48)  ·  United Kingdom (45)  ·  Australia (37)  ·  France (37)  ·  Italy (37)  ·  Spain (35)  ·  Poland (34)  ·  Netherlands (28)  ·  Austria (25)  ·  Czechia (22)  ·  Israel (22)  ·  Hungary (21)  ·  Japan (21)

Top investigators

Danielle Duffy, MD (2)  ·  Frank WG Leebeek, MD, PhD (2)  ·  Iris Jacobs, MD (2)  ·  Karina Meijer, MD, PhD (2)  ·  Steven Pipe, MD (2)

Results publications

PMID 40386832, PMID 36326435, PMID 33217027, PMID 42268494, PMID 23987198, PMID 24412910, PMID 26026936, PMID 30237305, PMID 37380568, PMID 39341368, PMID 40188458, PMID 40380356, PMID 17059476, PMID 17479360, PMID 18208533, PMID 18814020, PMID 19635187, PMID 19767078, PMID 19787352, PMID 19804533, PMID 20217199, PMID 20454851, PMID 20624109, PMID 20674826, PMID 21195947, PMID 21553933, PMID 21649849, PMID 21674136, PMID 21692906, PMID 21705277, PMID 21884533, PMID 21932110, PMID 21982521, PMID 22823000, PMID 22856636, PMID 22859609, PMID 23249928, PMID 23410777, PMID 23590915, PMID 23718572, PMID 23781960, PMID 23935011, PMID 24112951, PMID 24229737, PMID 24266596, PMID 24504846, PMID 25377187, PMID 25381842, PMID 25458735, PMID 25606785

NIH funding

2009 (7), 2014 (7), 2018 (7), 2017 (5), 2023 (5), 2008 (4), 2019 (4), 2015 (3), 2025 (3), 2004 (2), 2005 (1), 2016 (1)